Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DynPort has successfully advanced six biodefense products into clinical development and one to licensure. Notably, its recombinant plague vaccine candidate rF1V reached Phase 2 trials, and the company licensed vaccinia immune globulin for smallpox vaccine adverse reactions. DVC specializes in managing complex product development programs through preclinical, clinical, manufacturing, regulatory submission stages—primarily under U.S. government contracts[1][5][10].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DynPort Vaccine Company.